Phase II Trial of Fenretinide (NSC 374551) in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fenretinide (Primary)
- Indications Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 25 Mar 2013 Biomarkers information updated
- 09 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2005 New trial record.